Live
- BJP releases ‘charge sheet’ against BJD govt
- District Nodal Officer Venkataramana announced the intermediate results
- She team that stopped child marriages
- Medical devices sector needs separate rules, says industry body AiMeD
- Andhra Paper declares lockout
- Opposition INDIA bloc working on 'one year, one PM' formula: PM Modi
- Delhi HC quashes FIR for outraging woman's modesty, orders man to assist Traffic Police for a month as settlement
- 'Apologise to families of farmers who committed suicide in Vidarbha', Amit Shah dares Sharad Pawar
- SC Collegium recommends appointment of a permanent judge in Chhattisgarh HC, extension of term of two judges
- U20 Men's football nationals: Telangana, Sikkim earn full points with easy win
Aurobindo Pharma Q2 net up 4.6%
Aurobindo Pharma Limited on Tuesday said its consolidated net profit (after JV share, minority interest) for the quarter ended September 30 was up by 4.6 per cent to Rs 639.5 crore against Rs 611.4 crore in the Q2FY19.
Hyderabad: Aurobindo Pharma Limited on Tuesday said its consolidated net profit (after JV share, minority interest) for the quarter ended September 30 was up by 4.6 per cent to Rs 639.5 crore against Rs 611.4 crore in the Q2FY19.
Revenues from operation grew by nearly 18 per cent to Rs 5600.5 crore. It was Rs 4,751.4 crore during the same period last fiscal, the company said.
Managing director of the firm N Govindarajan said, "We had another quarter of healthy performance where we continued to grow in the US and Europe, which are our focused geographies.
Our R&D (research and development) initiatives have been progressing well across the products basket and we have started clinical trials for our first biosimilar product in Q3FY20."
